SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol Myers Squibb Reports First Phase 3 Data for KarXT

Bristol Myers Squibb reported preliminary results from the first Phase 3 study of KarXT in Alzheimer's-related psychosis.

BMY

Related stories